Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 10,981 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $3.10 on Friday. Trevi Therapeutics, Inc. has a 12-month low of $0.97 and a 12-month high of $4.00. The company has a market capitalization of $218.35 million, a price-to-earnings ratio of -9.12 and a beta of 0.96. The firm’s fifty day moving average price is $2.87 and its 200 day moving average price is $2.87.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the previous year, the firm earned ($0.07) EPS. Analysts forecast that Trevi Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

TRVI has been the topic of a number of research reports. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Raymond James initiated coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 target price on the stock. Rodman & Renshaw initiated coverage on shares of Trevi Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, HC Wainwright initiated coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued a “buy” rating and a $6.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $7.80.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD purchased a new stake in Trevi Therapeutics during the 1st quarter worth $47,000. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth about $61,000. The Manufacturers Life Insurance Company increased its position in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares during the last quarter. American Century Companies Inc. increased its position in shares of Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after purchasing an additional 7,902 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Trevi Therapeutics in the 1st quarter worth about $208,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.